Resveratrol (Micronized).

Resveratrol is cleared quickly by sulfotransferases and UDP-glucuronosyltransferases in the gut wall and liver. Quercetin occupies those same conjugating enzymes, which leaves more unchanged resveratrol in circulation.

Piperine slows intestinal glucuronidation, the main first-pass route that removes resveratrol before it reaches the bloodstream. This is the same mechanism used to raise curcumin exposure and it is standard formulation practice.

Pterostilbene is resveratrol with two methoxy groups in place of hydroxyls, which makes it more lipophilic and slower to conjugate. The two share a scaffold and much of their signalling, so they overlap rather than act independently.

Sirtuin deacetylases consume NAD+ for every reaction, and resveratrol acts on SIRT1 activity. Nicotinamide riboside raises the NAD+ pool those enzymes draw on, so one supplies the substrate and the other the signal.

NMN feeds into NAD+ synthesis one step from the final product. Since sirtuin activity is limited by NAD+ availability, pairing it with a sirtuin-directed stilbene addresses supply and signal together.

Resveratrol dampens platelet aggregation by reducing thromboxane formation, and EPA competes with arachidonic acid for the same cyclooxygenase route. Taken together the effect on normal clotting adds.

Ginkgolide B antagonises platelet activating factor while resveratrol lowers thromboxane-driven aggregation. Both nudge normal platelet behaviour in the same direction, so the combination compounds it.

Nattokinase acts on fibrin while resveratrol acts on platelet aggregation. They hit different parts of normal clot formation, so the effect stacks.

Garlic sulfur compounds reduce platelet aggregation through their own thromboxane-linked route. Combined with resveratrol the two push normal platelet function the same way.

Resveratrol dissolves poorly in water and micronised powder still needs wetting to disperse. Phospholipid carriers form a mixed micelle that keeps the stilbene in solution through the gut.

Trans-resveratrol is practically insoluble in water and its uptake improves when it is presented in a lipid phase that supports mixed-micelle formation. Medium-chain triglycerides supply that phase without needing much bile. Micronisation and a lipid vehicle address the same bottleneck from two directions, one by surface area and one by solubilisation.

Phospholipid complexation wets the crystalline stilbene and keeps it dispersed through gastric transit rather than letting it re-aggregate. This is the standard formulation route for phytosome-type polyphenol products. The physicochemical basis is established; a blood-level figure for any given product has to come from that product's own data.

When resveratrol quenches a radical it becomes a phenoxyl radical itself, and ascorbate in the aqueous phase reduces phenoxyl species back to the parent phenol. That regeneration step is why polyphenols and ascorbate are formulated together. It is settled redox chemistry rather than a measured clinical outcome.

Alpha-tocopherol handles lipid peroxyl radicals inside membranes while stilbenes act largely at the membrane surface and in the aqueous phase. Each compartment needs its own reductant. The pairing covers both without either substituting for the other.

Dihydrolipoate regenerates ascorbate and glutathione, the two pools that in turn regenerate oxidised polyphenols. Adding it feeds the network a level upstream of resveratrol itself. Established biochemistry, with no combination trial for this specific pair.

Cysteine availability limits glutathione synthesis, and glutathione conjugation is one route by which oxidised stilbene quinones are handled. Supplying cysteine supports that capacity. The relationship is metabolic support rather than an additive effect on any endpoint.

Quinone and semiquinone products of stilbene oxidation are conjugated with glutathione before excretion. A high polyphenol load therefore draws on the pool rather than only adding to antioxidant capacity. Naming that two-way relationship is more accurate than calling it a straightforward synergy.

Ubiquinol is the membrane-resident reductant that regenerates tocopherol, sitting deeper in the lipid phase than a stilbene reaches. Resveratrol is described as acting on mitochondrial biogenesis signalling, a different node of the same organelle. The two overlap in target and not in mechanism.

Curcuminoids and stilbenes are both cleared rapidly by intestinal and hepatic glucuronidation and sulfation, and each can occupy the conjugating enzymes the other uses. In practice that can raise the free fraction of one or both in a way that has not been quantified in people. The two co-occur often in the polyphenol literature, which is a research pattern and not a demonstrated joint effect.

Catechins and stilbenes compete for the same SULT isoforms and efflux transporters in the enterocyte. Which partner gains exposure depends on dose and order. Read this as a formulation caution rather than an absorption strategy.

Grape seed proanthocyanidins come from the same fruit that gave resveratrol its name and are metabolised into phenolic acids by the same colonic bacteria. Together they raise total polyphenol substrate reaching the colon. Any effect beyond that shared handling has not been measured for the pair.

Stilbenes and other polyphenols form complexes with non-heme iron in the gut lumen and lower the fraction available for uptake. The same complexation also changes the redox behaviour of the metal. Spacing an iron dose away from a polyphenol dose is the practical consequence, and this is settled absorption chemistry.

Zinc binds phenolic hydroxyls in the lumen, which reduces free mineral at the absorptive surface. The size of the effect scales with the polyphenol dose taken alongside. Established chemistry, worth stating in any multi-ingredient formulation.

Copper complexed by a polyphenol can shift from an antioxidant to a pro-oxidant behaviour depending on conditions, and the free mineral available for absorption falls. The direction is condition dependent rather than fixed. Mechanistic grounding only.

Berberine activates AMPK by raising the AMP to ATP ratio, while resveratrol is described as acting on sirtuin signalling that intersects the same energy-sensing network. The convergence is mechanistic and mostly from cell and animal work. No human combination trial defines what the pairing does.

Melatonin is a direct radical scavenger in addition to its receptor role, and both compounds are described in the mitochondrial redox literature. The pairing is common in longevity-positioned formulas. Evidence for the combination in people has not been established.

Taurine is required for the modification of mitochondrial tRNA that supports respiratory chain protein synthesis, a different point in mitochondrial function from the signalling attributed to stilbenes. Formulations pair them on that non-overlap. The rationale is mechanistic and untested as a combination.

Urolithin A is a gut-derived ellagitannin metabolite studied for mitophagy signalling, while resveratrol is studied for mitochondrial biogenesis signalling. The two sit on opposite sides of the same turnover cycle. The framing comes from mechanistic work, not from a joint human trial.

Long-chain omega-3 triglycerides provide the lipid phase that a poorly soluble stilbene needs for micellar uptake, and they also change membrane fatty acid composition in their own right. The absorption argument is physicochemical and general to lipophilic polyphenols. Co-dosing with a fat-containing meal is the practical version of the same point.

Lycopene is a carotenoid that partitions deep into membranes and lipoproteins where a stilbene does not sit. Combining the two spreads antioxidant coverage across compartments. This is formulation reasoning rather than a tested pair.